ERBB2 and breast carcinoma: Historically, the development of effective treatments for breast cancer, such as Herceptin for HER2+ breast cancer and endocrine therapy for ER+ breast cancer, has been driven by observations of recurrent molecular aberrations in tumors that are associated with differential patient outcomes.